Katie Lapidus advises private and public companies of all stages on a variety of corporate matters including formation, financing activities, corporate governance and securities law compliance. Katie also represents companies and underwriters in initial public offerings and follow-on securities offerings and counsels public companies with respect to SEC reporting obligations.
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its up to $75 million debt financing. Partner Addison Pierce led the Cooley team, which included Courtney Tygesson, Madison Jones, Margaret Barreto and Katie Lapidus.
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.
Cara Therapeutics, Inc. -- $40 Million Royalty Interest Purchase and Sale Agreement
November 3, 2023
Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.
NewAmsterdam Pharma – $181.6 Million Follow-on Offering
June 6, 2023
Cooley advised the underwriters in NewAmsterdam Pharma’s $181.6 million follow-on offering. NewAmsterdam is a clinical-stage biopharmaceutical company with a mission to improve care of patients with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. Lawyers Eric Blanchard, Div Gupta, Jean Park, Minkyu Park, Charles York, and Katie Lapidus led the Cooley team.